Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Cash from Investing Activities (2017 - 2025)

Cue Biopharma's Cash from Investing Activities history spans 9 years, with the latest figure at -$6.8 million for Q3 2025.

  • For Q3 2025, Cash from Investing Activities fell 7006.12% year-over-year to -$6.8 million; the TTM value through Sep 2025 reached -$6.9 million, down 21148.48%, while the annual FY2024 figure was $32000.0, 99.87% down from the prior year.
  • Cash from Investing Activities for Q3 2025 was -$6.8 million at Cue Biopharma, down from -$27000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $15.0 million in Q1 2023 and bottomed at -$29.5 million in Q3 2022.
  • The 5-year median for Cash from Investing Activities is -$10500.0 (2021), against an average of $143750.6.
  • The largest YoY upside for Cash from Investing Activities was 978177.89% in 2022 against a maximum downside of 268263.64% in 2022.
  • A 5-year view of Cash from Investing Activities shows it stood at $511.0 in 2021, then soared by 978177.89% to $5.0 million in 2022, then rose by 0.02% to $5.0 million in 2023, then crashed by 100.02% to -$1000.0 in 2024, then crashed by 676700.0% to -$6.8 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Cash from Investing Activities are -$6.8 million (Q3 2025), -$27000.0 (Q2 2025), and -$150000.0 (Q1 2025).